# Case Report: Management of a BCR-ABL1-positive high-risk rhabdomyosarcoma patient using tyrosine kinase inhibitors

## TL;DR

This case report describes a high-risk rhabdomyosarcoma patient with a BCR-ABL1 fusion gene who achieved a complete response using tyrosine kinase inhibitors alongside standard treatment.

## Contribution

The first documented case of BCR-ABL1-positive rhabdomyosarcoma successfully treated with tyrosine kinase inhibitors.

## Key findings

- The patient achieved an early complete response after adding tyrosine kinase inhibitors to standard therapy.
- BCR-ABL1 fusion gene presence was identified in a high-risk rhabdomyosarcoma case.
- The case suggests potential for molecularly targeted therapy in rhabdomyosarcoma.

## Abstract

Rhabdomyosarcoma represents a prevalent type of soft tissue sarcoma encountered in pediatric patients. Despite multimodal intensified therapies encompassing surgical intervention, chemotherapy, and radiotherapy, the prognosis for patients with high-risk rhabdomyosarcoma remains notably unfavorable. To date, no definitive and efficacious molecularly targeted therapies have been established. This report describes the first documented case of a rhabdomyosarcoma patient harboring a positive BCR-ABL1 fusion gene. At the time of initial diagnosis, the patient presented with a primary tumor in the right thigh and extensive metastatic involvement affecting both lungs, pleura, mediastinum, pelvic cavity, and the right inguinal region, resulting in the classification of the case as high-risk. In addition to conventional multimodal therapy, early intervention using tyrosine kinase inhibitors was implemented, leading to the achievement of an early complete response.